Here are seven articles published by Becker's Hospital Review this past week highlighting new survey findings on the hospital supply chain, a safety warning from the Food and Drug Administration and more scrutiny of high drug prices, among other topics.
1. Glassdoor ranks supply chain manager as 18th best job in US
Supply chain manager ranked No. 18 on Glassdoor's list of the 50 best jobs in the U.S.
2. FDA issues warning on balloon obesity devices
The FDA is warning clinicians of potential risks associated with fluid-filled intragastric balloons to treat obesity.
3. 'Reciprocal approval' would benefit rare disease patients while putting other populations at risk, study finds
"Reciprocal approval" would allow the FDA to automatically sign off on new drugs already approved in other countries. While some healthcare players believe this strategy could help lower drug prices and give patients access to treatments sooner, the tactic would pose a threat to much of the population, according to a new study in BMJ Open.
4. Survey: 25% of hospital staff witness expired or recalled product used on a patient
Supply chain improvements create better quality and promote patient safety, according to a new survey from Cardinal Health.
5. Pharma execs: Deregulated FDA will make it harder to get drugs covered by insurers
Some pharmaceutical executives fear President Donald Trump's call for a deregulated FDA would make it harder for drugmakers to gain insurance coverage for new treatments.
6. Supply chain tip of the week: Don't assume supply chain parity
Tom Fox, a managing director at the healthcare consulting firm Novia Strategies, shared a tip with Becker's Hospital Review about standardizing products and contract prices.
7. Sen. Sanders to Marathon: 'We're going to be your worst nightmare'
Marathon Pharmaceuticals' $89,000 price tag for its newly approved Duchenne muscular dystrophy drug has drawn criticism from many lawmakers, including Sen. Bernie Sanders, I-Vt.
More articles on supply chain:
Winter storms exacerbate blood shortage in New England
Sen. Sanders to drugmaker: 'We're going to be your worst nightmare'
Integra to buy J&J's neurosurgery business for $1B